Enhertu (trastuzumab deruxtecan), Daiichi Sankyo / AstraZeneca ’s HER2-directed antibody drug conjugate, is on track to becoming approved in the EU for an expanded indication which will include treat
The therapeutic indications of two EU-approved cancer drugs, Keytruda (pembrolizumab) and Bavencio (avelumab), are set to be further expanded after the European Medicines Agency recommended in favor o
The presentation of top-line Phase III clinical data on Taiho Oncology Inc. ’s lead product TAS-102 in May and June signaled the acceleration of the company’s plans to develop a commercial presence i
IN VITRO DIAGNOSTICS Mergers & Acquisitions Amgen Inc. deCode genetics EHF Amgen Inc. has acquired closely held human genetics firm deCODE genetics EHF for $415mm in cash. (Dec.) DeCODE was fo